Therefore, we propose that the evaluation of the expression levels of the genes involved in the RB/E2F pathway can be used in the monitoring of patients with astrocytomas in clinical practice and for the prognostic indication of disease progression. The gene discussed is RB1; the disease is astrocytoma (excluding glioblastoma).